3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Dermatologic
1
Conditions
Keratosis, Actinic
7
Keratosis
3
Waldenstrom Macroglobulinemia
1
Sezary Syndrome
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Neoplasms
1
Mycosis Fungoides
1
Lymphoproliferative Disorders
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Intraocular Lymphoma
1
Immunoblastic Lymphadenopathy
1
Hodgkin Disease
1
Burkitt Lymphoma
1
Interventions
Cyclophosphamide
6
fludarabine phosphate
5
Peripheral Blood Stem Cell Transplantation
5
Cyclosporine
4
Antilymphocyte Serum
4
Aminolevulinic Acid
4
Whole-Body Irradiation
3
Tacrolimus
3
Mycophenolic Acid
3
Methotrexate
3
Etoposide
3
Epoetin Alfa
3
Darbepoetin alfa
3
Busulfan
3
Sirolimus
2
Morphine
2
Methylprednisolone
2
Melphalan
2
Filgrastim
2
Biopsy
2
tremelimumab
1
tirbanibulin
1
pyroxamide
1
perillyl alcohol
1
ferrous sulfate
1
ferric gluconate
1
arginine butyrate
1
Triamcinolone
1
Therapeutics
1
Tetradecanoylphorbol Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Precancerous Conditions
×
tirbanibulin
×
Dermatologic
×
Clear all
NCT06135415
2026-03-25
TirbAKare
Almirall, S.A.
Phase 3
Completed
280 enrolled